Dyadic International (DYAI) Total Current Liabilities (2017 - 2026)
Dyadic International (DYAI) posted Total Current Liabilities of $3.2 million for Q1 2026, down 13.65% sequentially from $3.7 million in Q4 2025, and up 62.26% YoY from $2.0 million in Q1 2025.
Dyadic International (DYAI) Total Current Liabilities (2017 - 2026) Analysis & Trends
Dyadic International has reported Total Current Liabilities for 10 years, with the latest figure at $3.2 million in Q1 2026.
- Quarterly Total Current Liabilities rose 62.26% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 62.26% YoY) and the FY2025 annual result came in at $3.7 million, up 50.62% from the prior year.
- Total Current Liabilities eased to $3.2 million in Q1 2026 per DYAI's latest filing, from $3.7 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $1.8 billion in Q1 2022 and troughed at $1.5 million in Q3 2023.
- A 5-year average of $109.9 million and a median of $2.4 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 70319.08% in 2022, then slumped 99.9% in 2023.
- Over 5 years, Total Current Liabilities stood at $2.4 million in 2022, then decreased by 8.04% to $2.3 million in 2023, then increased by 8.71% to $2.4 million in 2024, then jumped by 50.62% to $3.7 million in 2025, then fell by 13.65% to $3.2 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $3.2 million, $3.7 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 630.93 Mn |
| 10 | Dyadic International | 19.83 Mn | 19.83 Mn | - | 3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.18 Mn |
| Dec 31, 2025 | 3.69 Mn |
| Sep 30, 2025 | 4.05 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 1.88 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Sep 30, 2022 | 2.39 Mn |
| Jun 30, 2022 | 3.40 Mn |
| Mar 31, 2022 | 1.83 Bn |
| Dec 31, 2021 | 2.56 Mn |
| Sep 30, 2021 | 1.96 Mn |
| Jun 30, 2021 | 3.29 Mn |